GlobeNewswire: BioSig Technologies, Inc. Contains the last 10 of 338 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:26:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/20/2832018/0/en/BioSig-Announces-Reduction-of-its-Workforce.html?f=22&fvtc=4&fvtv=17201BioSig Announces Reduction of its Workforce 2024-02-20T15:00:00Z<![CDATA[Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations.]]>https://www.globenewswire.com/news-release/2024/02/06/2824332/0/en/BioSig-s-PURE-EP-Platform-with-New-Near-Field-Tracking-Algorithm-Surpasses-100-Patient-Cases.html?f=22&fvtc=4&fvtv=17201BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases2024-02-06T13:30:00Z<![CDATA[Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. ]]>https://www.globenewswire.com/news-release/2024/01/31/2821436/0/en/BioSig-Announces-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=17201BioSig Announces Reverse Stock Split2024-01-31T16:15:00Z<![CDATA[Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024]]>https://www.globenewswire.com/news-release/2024/01/30/2820012/0/en/BioSig-Announces-Cost-Reductions-to-Improve-its-Financial-Standing-and-Shifts-its-Core-Strategy.html?f=22&fvtc=4&fvtv=17201BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy2024-01-30T13:30:00Z<![CDATA[Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to reduce annual cash burn by 50%. The Company is reducing its internal workforce, which is expected to be completed by January 31. The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform.]]>https://www.globenewswire.com/news-release/2023/12/06/2792055/0/en/BioSig-Issues-Letter-to-Shareholders-Detailing-Technology-Innovations-and-Strategic-Focus-for-2024.html?f=22&fvtc=4&fvtv=17201BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 20242023-12-06T19:20:00Z<![CDATA[Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.]]>https://www.globenewswire.com/news-release/2023/11/13/2779532/0/en/BioSig-Announces-2-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=17201BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules2023-11-13T21:30:00Z<![CDATA[Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants.]]>https://www.globenewswire.com/news-release/2023/11/09/2777274/0/en/BioSig-Announces-2-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=17201BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules2023-11-09T13:00:00Z<![CDATA[Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules.]]>https://www.globenewswire.com/news-release/2023/11/07/2775055/0/en/BioSig-Appoints-Global-MedTech-Leader-Fred-Hrkac-as-New-Executive-VP.html?f=22&fvtc=4&fvtv=17201BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP2023-11-07T13:00:00Z<![CDATA[32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson & Johnson’s original cardiology/electrophysiology business from $22M to $500M in 7 years 32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson & Johnson’s original cardiology/electrophysiology business from $22M to $500M in 7 years]]>https://www.globenewswire.com/news-release/2023/11/02/2772262/0/en/BioSig-s-New-PURE-EP-Subscription-Model-Adopted-by-Mayo-Clinic-Phoenix-for-World-Class-Cardiac-Care.html?f=22&fvtc=4&fvtv=17201BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care2023-11-02T12:00:00Z<![CDATA[PURE EP™ subscriber community now includes two of top three U.S. health systems in cardiology: Mayo Clinic-Phoenix and Cleveland Clinic PURE EP™ subscriber community now includes two of top three U.S. health systems in cardiology: Mayo Clinic-Phoenix and Cleveland Clinic]]>https://www.globenewswire.com/news-release/2023/11/01/2771177/0/en/BioSig-Adds-Five-New-Patent-Awards-to-100-Total-Patent-Portfolio-Covering-Digital-Signal-Processing-Technology-and-AI.html?f=22&fvtc=4&fvtv=17201BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI2023-11-01T12:30:00Z<![CDATA[IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific]]>